Baudouin C. The pathology of dry eye. Surv Ophthalmol . 2001 Mar;45 Suppl 2:S211–S20. Review.
Baudouin C, Pisella PJ, et al. [Current treatments of xerophthalmia in Sjögren's syndrome] Rev Med Interne . 2004 May;25(5):376–382. Review. French.
Bombardieri M, Barone F, et al. Increased circulating levels and salivary gland expression of interleukin-18 in patients with Sjögren's syndrome: relationship with autoantibody production and lymphoid organization of the periductal inflammatory infiltrate. Arthritis Res Ther . 2004;6(5):R447–R456.
Brito-Zeron P, Ramos Casals M, et al. Circulating monoclonal immunoglobulins in Sjogren syndrome: prevalence and clinical significance in 237 patients. Medicine ( Baltimore ). 2005 Mar;84(2):90–97.
Carsons S. The New Sjögren's Syndrome Handbook 1998 . New York : Oxford University Press.
Derk CT, Vivino FB. A primary care approach to Sjögren's syndrome: helping patients cope with sicca symptoms, extraglandular manifestations. Postgrad Med . 2004 Sep;116(3):49–54, 59, 65. Review.
Fife RS, Chase WF, et al. Cevimeline for the treatment of xerostomia in patients with Sjogren syndrome: a randomized trial. Arch Intern Med . 2002 Jun 10;162(11):1293–1300.
Gerli R, Bertotto A, et al. Anti-CD3 and anti-CD2-induced Tcell activation in primary Sjögren's syndrome. Clin Exp Rheumatol . 1989 Sep-Oct;7(Suppl. 3):S129-S134.
Glaser R, Rabin B, et al. Stress-induced immunomodulation: implications for infectious diseases. JAMA . 1999 Jun 23–30;281(24):2268–2270.
Hadden JW, Hadden EM. Therapy of secondary T-cell immunodeficiencies with biological substances and drugs. Med Oncol Tumor Pharmacother . 1989;6(1):11.
Harbige LS. Dietary n-6 and n-3 fatty acids in immunity and autoimmune disease. Proc Nutr Soc . 1998 Nov;57(4):555–562.
Hayashi Y, Arakaki R, et al. Apoptosis and estrogen deficiency in primary Sjogren syndrome. Curr Opin Rheumatol . 2004 Sep;16(5):522–526. Review. Erratum in: Curr Opin Rheumatol . 2004 Nov;16(6):753.
Hsu S, Dickinson DP, Qin H, et al. Inhibition of autoantigen expression by (-)-epigallocatechin-3-gallate (the major constituent of green tea) in normal human cells. J Pharmacol Exp Ther. 2005 Nov;315(2):805-11.
Horrobin DF. Loss of delta-6-desaturase activity as a key factor in aging. Med Hypotheses 1981 Sep;7(9):1211–1220.
Horrobin DF. Essential fatty acid metabolism in diseases of connective tissue with special reference to scleroderma and to Sjögren's syndrome. Med Hypotheses . 1984 July;14(3):233–247.
Horrobin DF. Essential fatty acid and prostaglandin metabolism in Sjögren's syndrome, systemic sclerosis and rheumatoid arthritis. Scand J Rheumatol . Suppl. 1986;61:242–245.
Ishimaru N, Saegusa K, et al. Estrogen deficiency accelerates autoimmune exocrinopathy in murine Sjögren's syndrome through fas-mediated apoptosis. Am J Pathol . 1999 Jul;155(1):173–181.
Klimberg VS, Salloum RM, et al. Oral glutamine accelerates healing of the small intestine and improves outcome after whole abdominal radiation. Arch Surg . 1990 Aug;125(8):1040–1045.
Kouttab NM , Prada M, et al. Thymomodulin: biological properties and clinical applications. Med Oncol Tumor Pharmacother . 1989;6(1):5.
Kujawa A, Rozycki R. [Immunological phenomenons in the pathology of the tear film. Is cyclosporine the turn point in the Sjögren's syndrome treatment? Preliminary report] Klin Oczna . 2004;106(3 Suppl):489–491. Polish.
Lazarus MN, Isenberg DA. Development of additional autoimmune diseases in a population of patients with primary Sjogren's syndrome. Ann Rheum Dis . 2005 Jul;64(7):1062-4.
Lynge Pedersen AM, Bardow A, et al. Salivary changes and dental caries as potential oral markers of autoimmune salivary gland dysfunction in primary Sjögren's syndrome. BMC Clin Pathol . 2005 Mar 1;5(1):4
Mahoney EJ, Spiegel JH. Sjögren's disease. Otolaryngol Clin North Am . 2003 Aug;36(4):733–745. Review.
Mariette X. Current and potential treatments for primary Sjögren's syndrome. Joint Bone Spine . 2002 Jun;69(4):363–366. Review.
Nusair S, Rubinow A. The use of oral pilocarpine in xerostomia and Sjögren's syndrome. Semin Arthritis Rheum . 1999 Jun;28(6):360–367.
Oxholm P, Manthorpe R, et al. Patients with primary Sjögren's syndrome treated for two months with evening primrose oil. Scand J Rheumatol . 1986;15(2):103–108.
Oxholm P, Asmussen K, et al. Essential fatty acid status in cell membranes and plasma of patients with primary Sjögren's syndrome. Correlations to clinical and immunologic variables using a new model for classification and assessment of disease manifestations. Prostaglandins Leukot Essent Fatty Acids . 1998 Oct;59(4):239–245.
Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol . 2005 Apr;98(4):1154–1162.
Rousso E, Noel E, et al. [Recurrent facial palsy, primary Gougerot-Sjögren's syndrome and vitamin B12 deficiency] Presse Med . 2005 Jan 29;34(2 Pt 1):107–108. French.
Ship JA, Fox PC, et al. Treatment of primary Sjögren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial. IFN Protocol Study Group. J Interferon Cytokine Res . 1999 Aug;19(8):943–951.
Sjögren's Syndrome Foundation. Available at: www.Sjögren's.org . Accessed October 10, 2005.
Stevenson HA, Jones ME, et al. UK patients with primary Sjögren's syndrome are at increased risk from clinical depression. Gerodontology . 2004 Sep;21(3):141–145.
Talal N. Overview of Sjögren's syndrome. J Dent Res . 1987 Feb;66(Spec No):672–674.
Tishler M, Paran D, et al. Allergic disorders in primary Sjögren's syndrome. Scand J Rheumatol . 1998;27(3):166–169.
Tsubota K, Monden Y, et al. New treatment of dry eye: the effect of calcium ointment through eyelid skin delivery. Br J Ophthalmol . 1999 Jul;83(7):767–770.
Valtysdottir ST , Wide L, et al. Low serum dehydroepiandrosterone sulfate in women with primary Sjögren's syndrome as an isolated sign of impaired HPA axis function. J Rheumatol . 2001 Jun;28(6):1259–1265.
Venables PJ. Sjögren's syndrome. Best Pract Res Clin Rheumatol . 2004 Jun;18(3):313–329. Review.
Wilson JL. Thymus extracts: an international literature review of clinical studies 1999. Available at http://www.hepatitiscfree.com/thymus_article2.html . Accessed October 10, 2005.
Wu AJ. The oral component of Sjögren's syndrome: pass the scalpel and check the water. Curr Rheumatol Rep . 2003 Aug;5(4):304–310.
Yamada S, Mori K, et al. Interferon alfa treatment for Sjögren's syndrome associated neuropathy. J Neurol Neurosurg Psychiatry . 2005 Apr;76(4):576–578.
Zhang NZ, Shi QS, et al. [Epidemiological studies on primary Sjögren's syndrome] Zhonghua Nei Ke Za Zhi . 1993 Aug;32(8):522–524. Chinese.